Sumnerogden9147

Dupilumab, the first biologic agent approved for AD, has now been well studied in patients aged 6 years and older, with expanded indication down to 6 years of age.Cutaneous T-cell lymphoma (CTCL) represents a diagnostic challenge because of its large symptomatic overlap with other common skin conditions such as atopic dermatitis (AD) and psoriasis. Dupilumab has offered promising results in AD treatment; however, concerns exist that its use may exacerbate undiagnosed CTCL. We present a patient with CTCL and concomitant AD who experienced improvement in both CTCL blood involvement and AD following the addition of dupilumab therapy.Physicians and the general public may be underusing alcohol-based hand sanitizers based on the false perception that they are damaging to the skin. We describe the use of a screw-top toothpaste cap to approximate the necessary volume of alcohol-based sanitizer for adequate hand disinfection.At the end of the activity, participants will be able to Identify the risks of kidney disease and their consequences in patients with T2DM. Initiate evidence-based therapy to slow the progression of kidney disease in patients with T2DM and CKD. Become familiar with the mineralocorticoid receptor antagonist and endothelin receptor antagonist under latephase investigation.After participating in this activity on chronic obstructive pulmonary disease (COPD), family physicians will be better able to Identify symptomatic patients at increased risk of COPD to prompt early diagnostic evaluation. Individualize evidence-based therapy with the goal of reducing COPD exacerbations and improving patient outcomes. Identify the role of fixed triple-combination inhalers as part of individualized therapy.Identify the benefits and limitations of statin therapy as a treatment option for lowering LDL-C. Intensify treatment in appropriate patients or refer for intensification. Describe the safety and efficacy of ezetimibe, bempedoic acid, PCSK9 inhibitors, LDL apheresis. Describe the safety and efficacy of medications in late-stage development or under review by the FDA for LDL-C reduction.After reading this review article on ADPKD, participants should be able to Identify people at high risk for ADPKD. Conduct a diagnostic evaluation. Initiate evidence-based therapy to slow kidney progression and treat extra-renal manifestations.At the conclusion of this activity, the family physician should be able to Describe the epidemiology of overweight and obesity in the United States. Describe the disease burden associated with being overweight (body mass index 25-30 kg/m2) and how to broach the topic of weight management with patients. Differentiate the safety and efficacy of 2 nonprocedural device treatments for people with overweight.Apply evidence-based diagnostic guidelines for patients who have clinical features consistent with insomnia. Use evidence-based guidelines to develop comprehensive treatment plans that include cognitive-behavioral therapy, pharmacologic treatment, and combination therapies to achieve optimal outcomes Identify basic elements of cognitivebehavioral therapy for insomnia Differentiate among medications FDA-approved for treating insomnia by discussing mechanism of action, safety, efficacy, and use.Identify the burden experienced by patients with dementia-related delusions and hallucinations. Assess patients with dementia for the presence of delusions and hallucinations. Individualize treatment in patients with dementia-related delusions and hallucinations. Align treatment of patients with Parkinson's psychosis with current recommendations.Acute pain often is treated with over-the-counter (OTC) therapeutics, including non-steroidal anti-inflammatory drugs (NSAIDs). However, not all NSAIDs are equally effective for treating different types of acute pain. In this article, we review the data supporting the use of OTC naproxen to effectively treat a variety of types of acute pain, including dysmenorrhea, headache, and dental pain, as well as review adverse effects. This information can be used to provide appropriate treatment for patients experiencing acute pain and help prevent progression to chronic pain.Describe the epidemiology of heart failure in people with diabetes mellitus. Implement evidence-based nonpharmacologic and pharmacologic therapies for heart failure with preserved ejection fraction and heart failure with reduced ejection fraction as recommended in current guidelines. Characterize the role of glucose-lowering medications, focusing on the sodium glucose cotransporter-2 inhibitors, for the treatment of people with type 2 diabetes mellitus.Describe the multiple symptoms of irritable bowel syndrome (IBS) and their impact on quality of life. Use a staged strategy for the diagnostic evaluation of IBS based on history and physical examination, including Rome IV criteria. Ridaforolimus Individualize treatment for IBS based on an evolving understanding of pathophysiologic mechanisms using evidence-based therapies to address patient concerns and improve quality of life.Identify common shortfalls in the typical American diet. Address the link between poor diet quality and chronic disease. Identify patients at risk for vitamin deficiency and potential vitamin-drug interactions. Recognize patients with vitamin and mineral deficiencies. Partner with patients regarding selection and appropriate use of vitamin and mineral supplements to achieve recommended dietary allowances.Psoriasis is a chronic inflammatory skin disease affecting 2% to 3% of individuals worldwide. However, the majority of clinical data are in white patients, with limited data in patients of color. We present 3 cases of psoriasis representative of patients presenting to an urban and racially diverse hospital-based dermatology clinic in Toronto, Ontario, Canada, to illustrate the differences in psoriasis in patients of color compared to white patients. We review the differences in the morphology, presentation, treatment, and psychosocial impact of psoriasis in this population. We also discuss the importance of early diagnosis, treatment considerations, and education in dermatology training programs regarding psoriasis in patients of color.